Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 786

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 786
---
:--|:--|:-----|:--|:--|:-----|---:|:--|:---------------------------|
| Unrealized gains on available-for-sale marketable securities: |   | ​                       |   |   | ​    |   |   | ​    |    |   |                            |
| Realized gains on sales of securities                         | ​ | $                       | — | ​ | $    | — | ​ | $    | 39 |   | Other income, net          |
| Income tax effect                                             | ​ |                         | — | ​ |      | — | ​ |      |  — |   | Benefit from income taxes  |
| Realized gains on sales of securities, net of tax             | ​ | $                       | — | ​ | $    | — | ​ | $    | 39 | ​ | ​                          |

5.Inventory, net

Inventories consist of the following:

| ​                                       | ​ 
 ​ | ​ |                 ​ 
 December 31, 2023 | ​ | ​ |                 ​ 
 December 31, 2022 |
|:----------------------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Raw materials                           | ​ | $ |             2,639 | ​ | $ |             1,918 |
| Work-in-process                         | ​ |   |               708 | ​ |   |               499 |
| ​                                       | ​ | ​ |             3,347 | ​ | ​ |             2,417 |
| Less Inventory Reserve for Obsolescence | ​ |   |              -526 | ​ |   |               -34 |
| Total                                   | ​ | $ |             2,821 | ​ | $ |             2,383 |

As of December 31, 2023 and December 31, 2022, inventory balances include inventory costs subsequent to regulatory approval of KORSUVA injection on August 23, 2021. During the years ended December 31, 2023 and 2022, the Company wrote down$ 526and$ 34, respectively, of commercial supply inventory due to obsolescence. There werenowrite-downs of commercial supply inventory during the year ended December 31, 2021.

F-56

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per